{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:11:02Z","timestamp":1772277062388,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vhri.2022.08.015","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T20:09:21Z","timestamp":1667592561000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Budget Impact Analysis of Nusinersen for Spinal Muscular Atrophy in China"],"prefix":"10.1016","volume":"34","author":[{"given":"Chengaxin","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binyan","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.vhri.2022.08.015_bib1","first-page":"1460","article-title":"Expert Consensus of Spinal muscular atrophy","volume":"99","year":"2019","journal-title":"Natl Med J China"},{"issue":"8","key":"10.1016\/j.vhri.2022.08.015_bib2","first-page":"634","article-title":"Therapeutic progress in spinal muscular atrophy","volume":"54","author":"Yang","year":"2016","journal-title":"Chin J Pediatr J Pediatr"},{"issue":"1","key":"10.1016\/j.vhri.2022.08.015_bib3","first-page":"70","article-title":"Economic burden of spinal muscular atrophy in the United States: a contemporary assessment","volume":"23","author":"Droege","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.vhri.2022.08.015_bib4","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/j.nmd.2019.06.324","article-title":"Burden of illness of spinal muscular atrophy type 1 (SMA1)","volume":"29","author":"Droege","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"suppl 15","key":"10.1016\/j.vhri.2022.08.015_bib5","first-page":"P4.4","article-title":"Spinal muscular atrophy: a review of epidemiology, burden and unmet needs","volume":"92","author":"Callan","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.vhri.2022.08.015_bib6","first-page":"S50","article-title":"Healthcare resource utilization and costs of spinal muscular atrophy care in the us Medicaid population","volume":"23","author":"Hall","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.015_bib7","doi-asserted-by":"crossref","first-page":"A282","DOI":"10.1016\/j.jval.2015.03.1645","article-title":"The economic burden of spinal muscular atrophy","volume":"18","author":"Armstrong","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2022.08.015_bib8","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/j.jval.2018.09.2008","article-title":"Healthcare costs of patients with spinal muscular atrophy","volume":"21","author":"D\u2019Angiolella","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2022.08.015_bib10","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"6","key":"10.1016\/j.vhri.2022.08.015_bib11","first-page":"845","article-title":"Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez","year":"2019"},{"key":"10.1016\/j.vhri.2022.08.015_bib12","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.jval.2019.04.1648","article-title":"Cost-effectiveness of nusinersen and onasemnogene abeparvovec for infantile-onset spinal muscular atrophy (Type I SMA) in the US","volume":"22","author":"Thokala","year":"2019","journal-title":"Value Health"},{"issue":"18","key":"10.1016\/j.vhri.2022.08.015_bib14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"15 Suppl","key":"10.1016\/j.vhri.2022.08.015_bib15","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1212\/WNL.94.15_supplement.1640","article-title":"Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study","volume":"94","author":"Castro","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.vhri.2022.08.015_bib16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.015_bib17","first-page":"211","article-title":"Hospitalization cost and influencing factors of pneumonia with children in a certain hospital in Beijing","volume":"15","author":"Hu","year":"2018","journal-title":"Chin J Health Inf Manage"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:13:59Z","timestamp":1761941639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109922001820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":15,"alternative-id":["S2212109922001820"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.08.015","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budget Impact Analysis of Nusinersen for Spinal Muscular Atrophy in China","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}